Biocon Biologics Ltd. , a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ) : VTRS ). Under the agreement, Biocon Biologics Ltd. (BBL) will acquire Viatris’ biosimilars business to create a fully integrated global biosimilars business. It is estimated that, in the next year, the revenues of this acquired company will be USD 1 billion. Viatris will receive compensation of up to USD 3.335 billion in cash and shares.
Biocon Biologics to acquire biosimilar assets from Viatris raising up to USD 3.335 billion in equity and cash
